This article is part of the supplement: Practical guide for allergy and immunology in Canada

Open Access Highly Accessed Review

Asthma

Harold Kim1,2,3* and Jorge Mazza1,3

  • * Corresponding author: Harold Kim

Author Affiliations

1 University of Western Ontario, London, Ontario, Canada

2 McMaster University, Hamilton, Ontario, Canada

3 Allergy Clinic, London Health Sciences Centre, London, Ontario, Canada

For all author emails, please log on.

Allergy, Asthma & Clinical Immunology 2011, 7(Suppl 1):S2 doi:10.1186/1710-1492-7-S1-S2

Published: 10 November 2011

Abstract

Asthma is the most common respiratory disorder in Canada. Despite significant improvement in the diagnosis and management of this disorder, the majority of Canadians with asthma remain poorly controlled. In most patients, however, control can be achieved through the use of avoidance measures and appropriate pharmacological interventions. Inhaled corticosteroids (ICSs) represent the standard of care for the majority of patients. Combination ICS/long-acting beta2-agonists (LABA) inhalers are preferred for most adults who fail to achieve control with ICS therapy. Allergen-specific immunotherapy represents a potentially disease-modifying therapy for many patients with asthma, but should only be prescribed by physicians with appropriate training in allergy. Regular monitoring of asthma control, adherence to therapy and inhaler technique are also essential components of asthma management. This article provides a review of current literature and guidelines for the appropriate diagnosis and management of asthma.